Promoting the stability and function of HIF through PHD inhibition has been recommended as a potent medicinal approach for ischemic diseases, cancer-related fatigue, and other oxidative pathological disorders resulting from anemia (Wu et al., 2016; Wu et al., 2017). Here, PDC is linked to anemia.